|
1
|
Rossiello F, Jurk D, Passos JF and d'Adda
di Fagagna F: Telomere dysfunction in ageing and age-related
diseases. Nat Cell Biol. 24:135–147. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
de Magalhães JP: Cellular senescence in
normal physiology. Science. 384:1300–1301. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kowald A, Passos JF and Kirkwood TBL: On
the evolution of cellular senescence. Aging Cell. 19:e132702020.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Varela-Eirín M and Demaria M: Cellular
senescence. Curr Biol. 32:R448–R452. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Afsar B and Afsar RE: Hypertension and
cellular senescence. Biogerontology. 24:457–478. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Roger L, Tomas F and Gire V: Mechanisms
and regulation of cellular senescence. Int J Mol Sci. 22:131732021.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Devarbhavi H, Asrani SK, Arab JP, Nartey
YA, Pose E and Kamath PS: Global burden of liver disease: 2023
Update. J Hepatol. 79:516–537. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zeng Q, Gong Y, Zhu N, Shi Y, Zhang C and
Qin L: Lipids and lipid metabolism in cellular senescence: Emerging
targets for age-related diseases. Ageing Res Rev. 97:1022942024.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Park J and Shin DW: Senotherapeutics and
their molecular mechanism for improving aging. Biomol Ther (Seoul).
30:490–500. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hayflick L and Moorhead PS: The serial
cultivation of human diploid cell strains. Exp Cell Res.
25:585–621. 1961. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Reimann M, Lee S and Schmitt CA: Cellular
senescence: Neither irreversible nor reversible. J Exp Med.
221:e202321362024. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ahmad A, Braden A, Khan S, Xiao J and Khan
MM: Crosstalk between the DNA damage response and cellular
senescence drives aging and age-related diseases. Semin
Immunopathol. 46:102024. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Basilicata MG, Sommella E, Scisciola L,
Tortorella G, Malavolta M, Giordani C, Barbieri M, Campiglia P and
Paolisso G: Multi-omics strategies to decode the molecular
landscape of cellular senescence. Ageing Res Rev. 111:1028242025.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Tchkonia T, Zhu Y, van Deursen J, Campisi
J and Kirkland JL: Cellular senescence and the senescent secretory
phenotype: therapeutic opportunities. J Clin Invest. 123:966–972.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Gasek NS, Kuchel GA, Kirkland JL and Xu M:
Strategies for targeting senescent cells in human disease. Nat
Aging. 1:870–879. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Safwan-Zaiter H, Wagner N and Wagner KD:
P16INK4A-More than a senescence marker. Life (Basel).
12:13322022.PubMed/NCBI
|
|
17
|
Ou HL and Schumacher B: DNA damage
responses and p53 in the aging process. Blood. 131:488–495. 2018.
View Article : Google Scholar
|
|
18
|
Gorgoulis V, Adams PD, Alimonti A, Bennett
DC, Bischof O, Bishop C, Campisi J, Collado M, Evangelou K,
Ferbeyre G, et al: Cellular senescence: Defining a path forward.
Cell. 179:813–827. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wang B, Han J, Elisseeff JH and Demaria M:
The senescence-associated secretory phenotype and its physiological
and pathological implications. Nat Rev Mol Cell Biol. 25:958–978.
2024. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Admasu TD, Rae M and Stolzing A:
Dissecting primary and secondary senescence to enable new
senotherapeutic strategies. Ageing Res Re. 70:1014122021.
View Article : Google Scholar
|
|
21
|
Wissler Gerdes EO, Zhu Y, Tchkonia T and
Kirkland JL: Discovery, development, and future application of
senolytics: Theories and predictions. FEBS J. 287:2418–2427. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhang L, Pitcher LE, Yousefzadeh MJ,
Niedernhofer LJ, Robbins PD and Zhu Y: Cellular senescence: A key
therapeutic target in aging and diseases. J Clin Invest.
132:e1584502022. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Espinosa De Ycaza AE, Søndergaard E,
Morgan-Bathke M, Carranza Leon BG, Lytle KA, Ramos P, Kirkland JL,
Tchkonia T and Jensen MD: Senescent cells in human adipose tissue:
A cross-sectional study. Obesity (Silver Spring). 29:1320–1327.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kirkland JL and Tchkonia T: Senolytic
drugs: From discovery to translation. J Intern Med. 288:518–536.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Naseem S, Hussain T and Manzoor S:
Interleukin-6: A promising cytokine to support liver regeneration
and adaptive immunity in liver pathologies. Cytokine Growth Factor
Rev. 39:36–45. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Widjaja AA, Chothani SP and Cook SA:
Different roles of interleukin 6 and interleukin 11 in the liver:
Implications for therapy. Hum Vaccin Immunother. 16:2357–2362.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yamagishi R, Kamachi F, Nakamura M,
Yamazaki S, Kamiya T, Takasugi M, Cheng Y, Nonaka Y, Yukawa-Muto Y,
Thuy LTT, et al: Gasdermin D-mediated release of IL-33 from
senescent hepatic stellate cells promotes obesity-associated
hepatocellular carcinoma. Sci Immunol. 7:eabl72092022. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Luciano-Mateo F, Cabré N, Fernández-Arroyo
S, Baiges-Gaya G, Hernández-Aguilera A, Rodríguez-Tomàs E,
Muñoz-Pinedo C, Menéndez JA, Camps J and Joven J: Chemokine C-C
motif ligand 2 overexpression drives tissue-specific metabolic
responses in the liver and muscle of mice. Sci Rep. 10:119542020.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Xu L, Chen Y, Nagashimada M, Ni Y, Zhuge
F, Chen G, Li H, Pan T, Yamashita T, Mukaida N, et al: CC chemokine
ligand 3 deficiency ameliorates diet-induced steatohepatitis by
regulating liver macrophage recruitment and M1/M2 status in mice.
Metabolism. 125:1549142021. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Yu X, Chen Y, Cui L, Yang K, Wang X, Lei
L, Zhang Y, Kong X, Lao W, Li Z, et al: CXCL8, CXCL9, CXCL10, and
CXCL11 as biomarkers of liver injury caused by chronic hepatitis B.
Front Microbiol. 13:10529172022. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Queck A, Bode H, Uschner FE, Brol MJ, Graf
C, Schulz M, Jansen C, Praktiknjo M, Schierwagen R, Klein S, et al:
Systemic MCP-1 levels derive mainly from injured liver and are
associated with complications in cirrhosis. Front Immunol.
11:3542020. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Yan J, Hu B, Shi W, Wang X, Shen J, Chen
Y, Huang H and Jin L: Gli2-regulated activation of hepatic stellate
cells and liver fibrosis by TGF-β signaling. Am J Physiol
Gastrointest Liver Physiol. 320:G720–G728. 2021. View Article : Google Scholar
|
|
33
|
Borkham-Kamphorst E and Weiskirchen R: The
PDGF system and its antagonists in liver fibrosis. Cytokine Growth
Factor Rev. 28:53–61. 2016. View Article : Google Scholar
|
|
34
|
Campana L, Esser H, Huch M and Forbes S:
Liver regeneration and inflammation: From fundamental science to
clinical applications. Nat Rev Mol Cell Biol. 22:608–624. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Wójcik M, Ramadori P, Blaschke M, Sultan
S, Khan S, Malik IA, Naz N, Martius G, Ramadori G and Schultze FC:
Immunodetection of cyclooxygenase-2 (COX-2) is restricted to tissue
macrophages in normal rat liver and to recruited mononuclear
phagocytes in liver injury and cholangiocarcinoma. Histochem Cell
Biol. 137:217–233. 2012. View Article : Google Scholar :
|
|
36
|
Lichtinghagen R, Michels D, Haberkorn CI,
Arndt B, Bahr M, Flemming P, Manns MP and Boeker KH: Matrix
metalloproteinase (MMP)-2, MMP-7, and tissue inhibitor of
metalloproteinase-1 are closely related to the fibroproliferative
process in the liver during chronic hepatitis C. J Hepatol.
34:239–247. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Thiele M, Johansen S, Gudmann NS, Madsen
B, Kjaergaard M, Nielsen MJ, Leeming DJ, Jacobsen S, Bendtsen F,
Møller S, et al: Progressive alcohol-related liver fibrosis is
characterised by imbalanced collagen formation and degradation.
Aliment Pharmacol Ther. 54:1070–1080. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Morio B, Panthu B, Bassot A and Rieusset
J: Role of mitochondria in liver metabolic health and diseases.
Cell Calcium. 94:1023362021. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Matsumoto T, Wakefield L and Grompe M: The
significance of polyploid hepatocytes during aging process. Cell
Mol Gastroenterol Hepatol. 11:1347–1349. 2021. View Article : Google Scholar :
|
|
40
|
Bu W, Sun X, Xue X, Geng S, Yang T, Zhang
J, Li Y, Feng C, Liu Q, Zhang X, et al: Early onset of pathological
polyploidization and cellular senescence in hepatocytes lacking
RAD51 creates a pro-fibrotic and pro-tumorigenic inflammatory
microenvironment. Hepatology. 81:491–508. 2025. View Article : Google Scholar
|
|
41
|
Lin S, Nascimento EM, Gajera CR, Chen L,
Neuhöfer P, Garbuzov A, Wang S and Artandi SE: Distributed
hepatocytes expressing telomerase repopulate the liver in
homeostasis and injury. Nature. 556:244–248. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Seo E, Kang H, Choi H, Choi W and Jun HS:
Reactive oxygen species-induced changes in glucose and lipid
metabolism contribute to the accumulation of cholesterol in the
liver during aging. Aging Cell. 18:e128952019. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Kiourtis C, Terradas-Terradas M, Gee LM,
May S, Georgakopoulou A, Collins AL, O'Sullivan ED, Baird DP,
Hassan M, Shaw R, et al: Hepatocellular senescence induces
multi-organ senescence and dysfunction via TGFβ. Nat Cell Biol.
26:2075–2083. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Aravinthan A, Shannon N, Heaney J, Hoare
M, Marshall A and Alexander GJ: The senescent hepatocyte gene
signature in chronic liver disease. Exp Gerontol. 60:37–45. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Trivedi P, Wang S and Friedman SL: The
power of plasticity-metabolic regulation of hepatic stellate cells.
Cell Metab. 33:242–257. 2021. View Article : Google Scholar
|
|
46
|
Dewidar B, Meyer C, Dooley S and
Meindl-Beinker AN: TGF-β in hepatic stellate cell activation and
liver fibrogenesis-updated 2019. Cells. 8:14192019. View Article : Google Scholar
|
|
47
|
Yang F, Li H, Li Y, Hao Y, Wang C, Jia P,
Chen X, Ma S and Xiao Z: Crosstalk between hepatic stellate cells
and surrounding cells in hepatic fibrosis. Int Immunopharmacol.
99:1080512021. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Yashaswini CN, Qin T, Bhattacharya D, Amor
C, Lowe S, Lujambio A, Wang S and Friedman SL: Phenotypes and
ontogeny of senescent hepatic stellate cells in metabolic
dysfunction-associated steatohepatitis. J Hepatol. 81:207–217.
2024. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
McConnell MJ, Kostallari E, Ibrahim S and
Iwakiri Y: The evolving role of liver sinusoidal endothelial cells
in liver health and disease. Hepatology. 78:649–669. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Wan Y, Li X, Slevin E, Harrison K, Li T,
Zhang Y, Klaunig JE, Wu C, Shetty AK, Dong XC and Meng F:
Endothelial dysfunction in pathological processes of chronic liver
disease during aging. FASEB J. 36:e221252022. View Article : Google Scholar
|
|
51
|
Hunt NJ, Kang SWS, Lockwood GP, Le Couteur
DG and Cogger VC: Hallmarks of aging in the liver. Comput Struct
Biotechnol J. 17:1151–1161. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Maeso-Díaz R, Ortega-Ribera M,
Fernández-Iglesias A, Hide D, Muñoz L, Hessheimer AJ, Vila S,
Francés R, Fondevila C, Albillos A, et al: Effects of aging on
liver microcirculatory function and sinusoidal phenotype. Aging
Cell. 17:e128292018. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Maeso-Díaz R, Ortega-Ribera M, Lafoz E,
Lozano JJ, Baiges A, Francés R, Albillos A, Peralta C, García-Pagán
JC, Bosch J, et al: Aging influences hepatic microvascular biology
and liver fibrosis in advanced chronic liver disease. Aging Dis.
10:684–698. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Li P, He K, Li J, Liu Z and Gong J: The
role of Kupffer cells in hepatic diseases. Mol Immunol. 85:222–229.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Yang W, Kim DM, Jiang W, Ai W, Pan Q,
Rahman S, Cai JJ, Brashear WA, Sun Y and Guo S: Suppression of
FOXO1 attenuates inflamm-aging and improves liver function during
aging. Aging Cell. 22:e139682023. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Yao J, Li Y and Wang H: The roles of
myeloid cells in aging-related liver diseases. Int J Biol Sci.
19:1564–1578. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Bird TG, Müller M, Boulter L, Vincent DF,
Ridgway RA, Lopez-Guadamillas E, Lu WY, Jamieson T, Govaere O,
Campbell AD, et al: TGFβ inhibition restores a regenerative
response in acute liver injury by suppressing paracrine senescence.
Sci Transl Med. 10:eaan12302018. View Article : Google Scholar
|
|
58
|
Fontana L, Zhao E, Amir M, Dong H, Tanaka
K and Czaja MJ: Aging promotes the development of diet-induced
murine steatohepatitis but not steatosis. Hepatology. 57:995–1004.
2013. View Article : Google Scholar
|
|
59
|
Trefts E, Gannon M and Wasserman DH: The
liver. Curr Biol. 27:R1147–R1151. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Sanders FWB and Griffin JL: De novo
lipogenesis in the liver in health and disease: More than just a
shunting yard for glucose. Biol Rev Camb Philos Soc. 91:452–468.
2016. View Article : Google Scholar :
|
|
61
|
Ghosh-Choudhary S, Liu J and Finkel T:
Metabolic regulation of cell fate and function. Trends Cell Biol.
30:201–212. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Andrews TS, Atif J, Liu JC, Perciani CT,
Ma XZ, Thoeni C, Slyper M, Eraslan G, Segerstolpe A, Manuel J, et
al: Single-cell, single-nucleus, and spatial RNA sequencing of the
human liver identifies cholangiocyte and mesenchymal heterogeneity.
Hepatol Commun. 6:821–840. 2022. View Article : Google Scholar
|
|
63
|
Horn P and Tacke F: Metabolic
reprogramming in liver fibrosis. Cell Metab. 36:1439–1455. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Foglia B, Beltrà M, Sutti S and Cannito S:
Metabolic reprogramming of HCC: A new microenvironment for immune
responses. Int J Mol Sci. 24:74632023. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Liu Q, Zhang X, Qi J, Tian X, Dovjak E,
Zhang J, Du H, Zhang N, Zhao J, Zhang Y, et al: Comprehensive
profiling of lipid metabolic reprogramming expands precision
medicine for HCC. Hepatology. 81:1164–1180. 2025. View Article : Google Scholar
|
|
66
|
Qu H, Liu J, Zhang D, Xie R, Wang L and
Hong: Glycolysis in chronic liver diseases: Mechanistic insights
and therapeutic opportunities. Cells. 12:19302023. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Lin J, Rao D, Zhang M and Gao Q: Metabolic
reprogramming in the tumor microenvironment of liver cancer. J
Hematol Oncol. 17:62024. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Moreno-Fernandez ME, Giles DA, Oates JR,
Chan CC, Damen MSMA, Doll JR, Stankiewicz TE, Chen X, Chetal K,
Karns R, et al: PKM2-dependent metabolic skewing of hepatic Th17
cells regulates pathogenesis of non-alcoholic fatty liver disease.
Cell Metab. 33:1187–1204.e9. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Rao J, Wang H, Ni M, Wang Z, Wang Z, Wei
S, Liu M, Wang P, Qiu J, Zhang L, et al: FSTL1 promotes liver
fibrosis by reprogramming macrophage function through modulating
the intracellular function of PKM2. Gut. 71:2539–2550. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Martin DE, Torrance BL, Haynes L and
Bartley JM: Targeting aging: Lessons learned from immunometabolism
and cellular senescence. Front Immunol. 12:7147422021. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Semenovich DS, Andrianova NV, Zorova LD,
Pevzner IB, Abramicheva PA, Elchaninov AV, Markova OV, Petrukhina
AS, Zorov DB and Plotnikov EY: Fibrosis development linked to
alterations in glucose and energy metabolism and
prooxidant-antioxidant balance in experimental models of liver
injury. Antioxidants (Basel). 12:16042023. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Harrington JS, Ryter SW, Plataki M, Price
DR and Choi AMK: Mitochondria in health, disease, and aging.
Physiol Rev. 103:2349–2422. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Guo Y, Guan T, Shafiq K, Yu Q, Jiao X, Na
D, Li M, Zhang G and Kong J: Mitochondrial dysfunction in aging.
Ageing Res Rev. 88:1019552023. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Amorim JA, Coppotelli G, Rolo AP, Palmeira
CM, Ross JM and Sinclair DA: Mitochondrial and metabolic
dysfunction in ageing and age-related diseases. Nat Rev Endocrinol.
18:243–258. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Mansouri A, Gattolliat CH and Asselah T:
Mitochondrial dysfunction and signaling in chronic liver diseases.
Gastroenterology. 155:629–647. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Zhang Y, Tian XL, Li JQ, Wu DS, Li Q and
Chen B: Mitochondrial dysfunction affects hepatic immune and
metabolic remodeling in patients with hepatitis B virus-related
acute-on-chronic liver failure. World J Gastroenterol. 30:881–900.
2024. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Xiang L, Shao Y and Chen Y: Mitochondrial
dysfunction and mitochondrion-targeted therapeutics in liver
diseases. J Drug Target. 29:1080–1093. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Reynolds JC, Lai RW, Woodhead JST, Joly
JH, Mitchell CJ, Cameron-Smith D, Lu R, Cohen P, Graham NA,
Benayoun BA, et al: MOTS-c is an exercise-induced
mitochondrial-encoded regulator of age-dependent physical decline
and muscle homeostasis. Nat Commun. 12:4702021. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
López-Otín C, Blasco MA, Partridge L,
Serrano M and Kroemer G: Hallmarks of aging: An expanding universe.
Cell. 186:243–278. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Cavaliere G, Catapano A, Trinchese G,
Cimmino F, Menale C, Petrella L and Mollica MP: Crosstalk between
adipose tissue and hepatic mitochondria in the development of the
inflammation and liver injury during ageing in high-fat diet fed
rats. Int J Mol Sci. 24:29672023. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Wang W, Wang C, Xu H and Gao Y: Aldehyde
dehydrogenase, liver disease and cancer. Int J Biol Sci.
16:921–934. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Thoudam T, Gao H, Jiang Y, Huda N, Yang Z,
Ma J and Liangpunsakul S: Mitochondrial quality control in
alcohol-associated liver disease. Hepatol Commun. 8:e05342024.
View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Eid N, Ito Y, Horibe A and Otsuki Y:
Ethanol-induced mitophagy in liver is associated with activation of
the PINK1-Parkin pathway triggered by oxidative DNA damage. Histol
Histopathol. 31:1143–1159. 2016.PubMed/NCBI
|
|
84
|
Hammoutene A, Biquard L, Lasselin J,
Kheloufi M, Tanguy M, Vion AC, Mérian J, Colnot N, Loyer X, Tedgui
A, et al: A defect in endothelial autophagy occurs in patients with
non-alcoholic steatohepatitis and promotes inflammation and
fibrosis. J Hepatol. 72:528–538. 2020. View Article : Google Scholar
|
|
85
|
Qu X, Yu J, Bhagat G, Furuya N, Hibshoosh
H, Troxel A, Rosen J, Eskelinen EL, Mizushima N, Ohsumi Y, et al:
Promotion of tumorigenesis by heterozygous disruption of the beclin
1 autophagy gene. J Clin Invest. 112:1809–1820. 2023. View Article : Google Scholar
|
|
86
|
Cichoż-Lach H and Michalak A: Oxidative
stress as a crucial factor in liver diseases. World J
Gastroenterol. 20:8082–8091. 2014. View Article : Google Scholar
|
|
87
|
Lee J, Kim J, Lee R, Lee E, Choi TG, Lee
AS, Yoon YI, Park GC, Namgoong JM, Lee SG and Tak E: Therapeutic
strategies for liver diseases based on redox control systems.
Biomed Pharmacother. 156:1137642022. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Hajam YA, Rani R, Ganie SY, Sheikh TA,
Javaid D, Qadri SS, Pramodh S, Alsulimani A, Alkhanani MF, Harakeh
S, et al: Oxidative stress in human pathology and aging: Molecular
mechanisms and perspectives. Cells. 11:5522022. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Bárcena B, Salamanca A, Pintado C,
Mazuecos L, Villar M, Moltó E, Bonzón-Kulichenko E, Vázquez J,
Andrés A and Gallardo N: Aging induces hepatic oxidative stress and
nuclear proteomic remodeling in liver from wistar rats.
Antioxidants (Basel). 10:15352021. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Jung YS, Radhakrishnan K, Hammad S, Müller
S, Müller J, Noh JR, Kim J, Lee IK, Cho SJ, Kim DK, et al:
ERRγ-inducible FGF23 promotes alcoholic liver injury through
enhancing CYP2E1 mediated hepatic oxidative stress. Redox Biol.
71:1031072024. View Article : Google Scholar
|
|
91
|
Jin J, Iakova P, Jiang Y, Medrano EE and
Timchenko NA: The reduction of SIRT1 in livers of old mice leads to
impaired body homeostasis and to inhibition of liver proliferation.
Hepatology. 54:989–998. 2021. View Article : Google Scholar
|
|
92
|
Gressler AE, Leng H, Zinecker H and Simon
AK: Proteostasis in T cell aging. Semin Immunol. 70:1018382023.
View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Hipp MS, Kasturi P and Hartl FU: The
proteostasis network and its decline in ageing. Nat Rev Mol Cell
Biol. 20:421–435. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Klaips CL, Jayaraj GG and Hartl FU:
Pathways of cellular proteostasis in aging and disease. J Cell
Biol. 217:51–63. 2018. View Article : Google Scholar :
|
|
95
|
Xia SW, Wang ZM, Sun SM, Su Y, Li ZH, Shao
JJ, Tan SZ, Chen AP, Wang SJ, Zhang ZL and Zheng SZ: Endoplasmic
reticulum stress and protein degradation in chronic liver disease.
Pharmacol Res. 161:1052182020. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Wei S, Wang Q, Zhou H, Qiu J, Li C, Shi C,
Zhou S, Liu R and Lu L: miR-455-3p alleviates hepatic stellate cell
activation and liver fibrosis by suppressing HSF1 expression. Mol
Ther Nucleic Acids. 16:758–769. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Tsao FHC, Barnes JN, Amessoudji A, Li Z
and Meyer KC: Aging-related and gender specific albumin misfolding
in Alzheimer's disease. J Alzheimers Dis Rep. 4:67–77. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Cuanalo-Contreras K, Schulz J, Mukherjee
A, Park KW, Armijo E and Soto C: Extensive accumulation of
misfolded protein aggregates during natural aging and senescence.
Front Aging Neurosci. 14:10901092023. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Recillas-Targa F: Cancer epigenetics: An
overview. Arch Med Res. 53:732–740. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Saul D and Kosinsky RL: Epigenetics of
aging and aging-associated diseases. Int J Mol Sci. 22:4012021.
View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Murphy SK, Yang H, Moylan CA, Pang H,
Dellinger A, Abdelmalek MF, Garrett ME, Ashley-Koch A, Suzuki A,
Tillmann HL, et al: Relationship between methylome and
transcriptome in patients with nonalcoholic fatty liver disease.
Gastroenterology. 145:1076–1087. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Gallon J, Coto-Llerena M, Ercan C, Bianco
G, Paradiso V, Nuciforo S, Taha-Melitz S, Meier MA, Boldanova T,
Pérez-Del-Pulgar S, et al: Epigenetic priming in chronic liver
disease impacts the transcriptional and genetic landscapes of
hepatocellular carcinoma. Mol Oncol. 16:665–682. 2022. View Article : Google Scholar :
|
|
103
|
Liu YR, Wang JQ, Huang ZG, Chen RN, Cao X,
Zhu DC, Yu HX, Wang XR, Zhou HY, Xia Q and Li J: Histone
deacetylase-2: A potential regulator and therapeutic target in
liver disease (review). Int J Mol Med. 48:1312021. View Article : Google Scholar :
|
|
104
|
Joanna F, van Grunsven LA, Mathieu V,
Sarah S, Sarah D, Karin V, Tamara V and Vera R: Histone deacetylase
inhibition and the regulation of cell growth with particular
reference to liver pathobiology. J Cell Mol Med. 13:2990–3005.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Morral N, Liu S, Conteh AM, Chu X, Wang Y,
Dong XC, Liu Y, Linnemann AK and Wan J: Aberrant gene expression
induced by a high fat diet is linked to H3K9 acetylation in the
promoter-proximal region. Biochim Biophys Acta Gene Regul Mech.
1864:1946912021. View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Sun C, Fan JG and Qiao L: Potential
epigenetic mechanism in non-alcoholic fatty liver disease. Int J
Mol Sci. 16:5161–5179. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Suter MA, Chen A, Burdine MS, Choudhury M,
Harris RA, Lane RH, Friedman JE, Grove KL, Tackett AJ and Aagaard
KM: A maternal high-fat diet modulates fetal SIRT1 histone and
protein deacetylase activity in nonhuman primates. FASEB J.
26:5106–5114. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Pazienza V, Borghesan M, Mazza T, Sheedfar
F, Panebianco C, Williams R, Mazzoccoli G, Andriulli A, Nakanishi T
and Vinciguerra M: SIRT1-metabolite binding histone macroH2A1.1
protects hepatocytes against lipid accumulation. Aging (Albany NY).
6:35–47. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
109
|
Kriss CL, Gregory-Lott E, Storey AJ,
Tackett AJ, Wahls WP and Stevens SM Jr: In vivo metabolic tracing
demonstrates the site-specific contribution of hepatic ethanol
metabolism to histone acetylation. Alcohol Clin Exp Res.
42:1909–1923. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Xiao Y, Hu Y and Liu S: Non-coding RNAs: A
promising target for early metastasis intervention. Chin Med J
(Engl). 136:2538–2550. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
111
|
Dongiovanni P, Meroni M, Longo M, Fargion
S and Fracanzani AL: miRNA signature in NAFLD: A turning point for
a non-invasive diagnosis. Int J Mol Sci. 19:39662018. View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Markovic J, Sharma AD and Balakrishnan A:
MicroRNA-221: A fine tuner and potential biomarker of chronic liver
injury. Cells. 9:17672020. View Article : Google Scholar : PubMed/NCBI
|
|
113
|
Sodum N, Kumar G, Bojja SL, Kumar N and
Rao CM: Epigenetics in NAFLD/NASH: Targets and therapy. Pharmacol
Res. 167:1054842021. View Article : Google Scholar : PubMed/NCBI
|
|
114
|
Maeso-Díaz R and Gracia-Sancho J: Aging
and chronic liver disease. Semin Liver Dis. 40:373–384. 2020.
View Article : Google Scholar
|
|
115
|
GBD 2019 Hepatitis B Collaborators:
Global, regional, and national burden of hepatitis B, 1990-2019: A
systematic analysis for the global burden of disease study 2019.
Lancet Gastroenterol Hepatol. 7:796–829. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
116
|
Liu Z, Lin C, Mao X, Guo C, Suo C, Zhu D,
Jiang W, Li Y, Fan J, Song C, et al: Changing prevalence of chronic
hepatitis B virus infection in China between 1973 and 2021: A
systematic literature review and meta-analysis of 3740 studies and
231 million people. Gut. 72:2354–2363. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
117
|
Kondo Y, Tsukada K, Takeuchi T, Mitsui T,
Iwano K, Masuko K, Itoh T, Tokita H, Okamoto H, Tsuda F, et al:
High carrier rate after hepatitis B virus infection in the elderly.
Hepatology. 18:768–774. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
118
|
Bellon M and Nicot C: Telomere dynamics in
immune senescence and exhaustion triggered by chronic viral
infection. Viruses. 9:2892017. View Article : Google Scholar : PubMed/NCBI
|
|
119
|
Feng W, Yu D, Li B, Luo OY, Xu T, Cao Y
and Ding Y: Paired assessment of liver telomere lengths in
hepatocellular cancer is a reliable predictor of disease
persistence. Biosci Rep. 37:BSR201606212017. View Article : Google Scholar : PubMed/NCBI
|
|
120
|
Tachtatzis PM, Marshall A, Arvinthan A,
Verma S, Penrhyn-Lowe S, Mela M, Scarpini C, Davies SE, Coleman N
and Alexander GJ: Chronic hepatitis B virus infection: The relation
between hepatitis b antigen expression, telomere length,
senescence, inflammation and fibrosis. PLoS One. 10:e01275112015.
View Article : Google Scholar : PubMed/NCBI
|
|
121
|
Adelakun AA, Adediji IO, Idowu OJ, Jegede
TF, Oluremi AS, Adepoju PO and Olaniyan OA: Prognostic significance
of serum telomerase activity in the monitoring of hepatitis B viral
infection. J Immunoassay Immunochem. 43:299–307. 2022. View Article : Google Scholar
|
|
122
|
Barnard A, Moch A and Saab S: Relationship
between telomere maintenance and liver disease. Gut Liver.
13:11–15. 2019. View Article : Google Scholar :
|
|
123
|
Bolukbas C, Bolukbas FF, Kocyigit A, Aslan
M, Selek S, Bitiren M and Ulukanligil M: Relationship between
levels of DNA damage in lymphocytes and histopathological severity
of chronic hepatitis C and various clinical forms of hepatitis B. J
Gastroenterol Hepatol. 21:610–616. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
124
|
Zhang Y, Cao W, Wang S, Zhang L, Li X,
Zhang Z, Xie Y and Li M: Epigenetic modification of hepatitis B
virus infection and related hepatocellular carcinoma. Virulence.
15:24212312024. View Article : Google Scholar : PubMed/NCBI
|
|
125
|
Idrissi ME, Hachem H, Koering C, Merle P,
Thénoz M, Mortreux F and Wattel E: HBx triggers either cellular
senescence or cell proliferation depending on cellular phenotype. J
Viral Hepat. 23:130–138. 2016. View Article : Google Scholar
|
|
126
|
Mastrodomenico M, Muselli M, Provvidenti
L, Scatigna M, Bianchi S and Fabiani L: Long-term immune protection
against HBV: Associated factors and determinants. Hum Vaccin
Immunother. 17:2268–2272. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
127
|
Zeng Z, Li L, Chen Y, Wei H, Sun R and
Tian Z: Interferon-γ facilitates hepatic antiviral T cell retention
for the maintenance of liver-induced systemic tolerance. J Exp Med.
213:1079–1093. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
128
|
Borgia M, Dal Bo M and Toffoli G: Role of
virus-related chronic inflammation and mechanisms of cancer
immune-suppression in pathogenesis and progression of
hepatocellular carcinoma. Cancers (Basel). 13:43872021. View Article : Google Scholar : PubMed/NCBI
|
|
129
|
Zhou X, Yang F, Yang Y, Hu Y, Liu W, Huang
C, Li S and Chen Z: HBV facilitated hepatocellular carcinoma cells
proliferation by up-regulating angiogenin expression through IL-6.
Cell Physiol Biochem. 46:461–470. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
130
|
Kim JR and Kim CH: Association of a high
activity of matrix metalloproteinase-9 to low levels of tissue
inhibitors of metal-loproteinase-1 and -3 in human hepatitis
B-viral hepatoma cells. Int J Biochem Cell Biol. 36:2293–2306.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
131
|
Bekçibaşı M, Deveci Ö, Oğuz A, Bozkurt F,
Dayan S and Çelen MK: Serum TNF-α, IL-1β, and IL-6 levels in
chronic HBV-infected patients. Int J Clin Pract. 75:e142922021.
View Article : Google Scholar
|
|
132
|
Rosenberg C, Bovin NV, Bram LV, Flyvbjerg
E, Erlandsen M, Vorup-Jensen T and Petersen E: Age is an important
determinant in humoral and T cell responses to immunization with
hepatitis B surface antigen. Hum Vaccin Immunother. 9:1466–1476.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
133
|
Eslam M, Sanyal AJ and George J;
International Consensus Panel: MAFLD: A consensus-driven proposed
nomenclature for metabolic associated fatty liver disease.
Gastroenterology. 158:1999–2014.e1. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
134
|
Noureddin M, Yates KP, Vaughn IA,
Neuschwander-Tetri BA, Sanyal AJ, McCullough A, Merriman R, Hameed
B, Doo E, Kleiner DE, et al: Clinical and histological determinants
of nonalcoholic steatohepatitis and advanced fibrosis in elderly
patients. Hepatology. 58:1644–1654. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
135
|
Gao Y, Zhang W, Zeng LQ, Bai H, Li J, Zhou
J, Zhou GY, Fang CW, Wang F and Qin XJ: Exercise and dietary
intervention ameliorate high-fat diet-induced NAFLD and liver aging
by inducing lipophagy. Redox Biol. 36:1016352020. View Article : Google Scholar : PubMed/NCBI
|
|
136
|
Dabravolski SA, Bezsonov EE and Orekhov
AN: The role of mitochondria dysfunction and hepatic senescence in
NAFLD development and progression. Biomed Pharmacother.
142:1120412021. View Article : Google Scholar : PubMed/NCBI
|
|
137
|
Baboota RK, Rawshani A, Bonnet L, Li X,
Yang H, Mardinoglu A, Tchkonia T, Kirkland JL, Hoffmann A, Dietrich
A, et al: BMP4 and Gremlin 1 regulate hepatic cell senescence
during clinical progression of NAFLD/NASH. Nat Metab. 4:1007–1021.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
138
|
Meijnikman AS, Herrema H, Scheithauer TPM,
Kroon J, Nieuwdorp M and Groen AK: Evaluating causality of cellular
senescence in non-alcoholic fatty liver disease. JHEP Rep.
3:1003012021. View Article : Google Scholar : PubMed/NCBI
|
|
139
|
Tomita K, Teratani T, Suzuki T, Oshikawa
T, Yokoyama H, Shimamura K, Nishiyama K, Mataki N, Irie R, Minamino
T, et al: p53/p66Shc-mediated signaling contributes to the
progression of non-alcoholic steatohepatitis in humans and mice. J
Hepatol. 57:837–843. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
140
|
Bi H, Zhou B, Yang J, Lu Y, Mao F and Song
Y: Whole-genome DNA methylation and gene expression profiling in
the livers of mice with nonalcoholic steatohepatitis. Life Sci.
329:1219512023. View Article : Google Scholar : PubMed/NCBI
|
|
141
|
Sim BC, Kang YE, You SK, Lee SE, Nga HT,
Lee HY, Nguyen TL, Moon JS, Tian J, Jang HJ, et al: Hepatic T-cell
senescence and exhaustion are implicated in the progression of
fatty liver disease in patients with type 2 diabetes and mouse
model with nonalcoholic steatohepatitis. Cell Death Dis.
14:6182023. View Article : Google Scholar : PubMed/NCBI
|
|
142
|
Kazankov K, Møller HJ, Lange A, Birkebaek
NH, Holland-Fischer P, Solvig J, Hørlyck A, Kristensen K, Rittig S,
Handberg A, et al: The macrophage activation marker sCD163 is
associated with changes in NAFLD and metabolic profile during
lifestyle intervention in obese children. Pediatr Obes. 10:226–233.
2015. View Article : Google Scholar
|
|
143
|
Hernández-Évole H, Jiménez-Esquivel N,
Pose E and Bataller R: Alcohol-associated liver disease:
Epidemiology and management. Ann Hepatol. 29:1011622024. View Article : Google Scholar
|
|
144
|
Mackowiak B, Fu Y, Maccioni L and Gao B:
Alcohol-associated liver disease. J Clin Invest. 134:e1763452024.
View Article : Google Scholar : PubMed/NCBI
|
|
145
|
Åberg F, Jiang ZG, Cortez-Pinto H and
Männistö V: Alcohol-associated liver disease-global epidemiology.
Hepatology. 80:1307–1322. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
146
|
Wan Y, McDaniel K, Wu N, Ramos-Lorenzo S,
Glaser T, Venter J, Francis H, Kennedy L, Sato K, Zhou T, et al:
Regulation of cellular senescence by miR-34a in alcoholic liver
injury. Am J Pathol. 187:2788–2798. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
147
|
Huda N, Kusumanchi P, Perez K, Jiang Y,
Skill NJ, Sun Z, Ma J, Yang Z and Liangpunsakul S: Telomere length
in patients with alcohol-associated liver disease: A brief report.
J Investig Med. 70:1438–1441. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
148
|
So-Armah K, Freiberg M, Cheng D, Lim JK,
Gnatienko N, Patts G, Doyle M, Fuster D, Lioznov D, Krupitsky E and
Samet J: Liver fibrosis and accelerated immune dysfunction
(immunosenescence) among HIV-infected Russians with heavy alcohol
consumption-an observational cross-sectional study. BMC
Gastroenterol. 20:12019. View Article : Google Scholar
|
|
149
|
Dou L, Shi X, He X and Gao Y: Macrophage
phenotype and function in liver disorder. Front Immunol.
10:31122020. View Article : Google Scholar : PubMed/NCBI
|
|
150
|
Wan J, Benkdane M, Alons E, Lotersztajn S
and Pavoine C: M2 kupffer cells promote hepatocyte senescence: An
IL-6-dependent protective mechanism against alcoholic liver
disease. Am J Pathol. 184:1763–1772. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
151
|
Chedid A, Mendenhall CL, Moritz TE, French
SW, Chen TS, Morgan TR, Roselle GA, Nemchausky BA, Tamburro CH,
Schiff ER, et al: Cell-mediated hepatic injury in alcoholic liver
disease. Veterans affairs cooperative study group 275.
Gastroenterology. 105:254–266. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
152
|
Suh YG and Jeong WI: Hepatic stellate
cells and innate immunity in alcoholic liver disease. World J
Gastroenterol. 17:2543–2551. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
153
|
Parola M and Pinzani M: Liver fibrosis:
Pathophysiology, pathogenetic targets and clinical issues. Mol
Aspects Med. 65:37–55. 2019. View Article : Google Scholar
|
|
154
|
Roehlen N, Crouchet E and Baumert TF:
Liver fibrosis: Mechanistic concepts and therapeutic perspectives.
Cells. 9:8752020. View Article : Google Scholar : PubMed/NCBI
|
|
155
|
Feng F, Wu J, Chi Q, Wang S, Liu W, Yang
L, Song G, Pan L, Xu K and Wang C: Lactylome analysis unveils
lactylation-dependent mechanisms of stemness remodeling in the
liver cancer stem cells. Adv Sci (Weinh). 11:e24059752024.
View Article : Google Scholar : PubMed/NCBI
|
|
156
|
Cheemerla S and Balakrishnan M: Global
epidemiology of chronic liver disease. Clin Liver Dis (Hoboken).
17:365–370. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
157
|
Smith A, Baumgartner K and Bositis C:
Cirrhosis: Diagnosis and management. Am Fam Physician. 100:759–770.
2019.PubMed/NCBI
|
|
158
|
Weiskirchen R, Weiskirchen S and Tacke F:
Organ and tissue fibrosis: Molecular signals, cellular mechanisms
and translational implications. Mol Aspects Med. 65:2–15. 2019.
View Article : Google Scholar
|
|
159
|
Ghafouri-Fard S, Abak A, Talebi SF,
Shoorei H, Branicki W, Taheri M and Akbari Dilmaghani N: Role of
miRNA and lncRNAs in organ fibrosis and aging. Biomed Pharmacother.
143:1121322021. View Article : Google Scholar : PubMed/NCBI
|
|
160
|
Wijayasiri P, Astbury S, Kaye P, Oakley F,
Alexander GJ, Kendall TJ and Aravinthan AD: Role of hepatocyte
senescence in the activation of hepatic stellate cells and liver
fibrosis progression. Cells. 11:22212022. View Article : Google Scholar : PubMed/NCBI
|
|
161
|
Li Y, Adeniji NT, Fan W, Kunimoto K and
Török NJ: Non-alcoholic fatty liver disease and liver fibrosis
during aging. Aging Dis. 13:1239–1251. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
162
|
Zhou Y, Zhang H, Yao Y, Zhang X, Guan Y
and Zheng F: CD4+ T cell activation and inflammation in
NASH-related fibrosis. Front Immunol. 13:9674102022. View Article : Google Scholar
|
|
163
|
Ajith A, Merimi M, Arki MK,
Hossein-Khannazer N, Najar M, Vosough M, Sokal EM and Najimi M:
Immune regulation and therapeutic application of T regulatory cells
in liver diseases. Front Immunol. 15:13710892024. View Article : Google Scholar : PubMed/NCBI
|
|
164
|
Wu NN, Wang L, Wang L, Xu X, Lopaschuk GD,
Zhang Y and Ren J: Site-specific ubiquitination of VDAC1 restricts
its oligomerization and mitochondrial DNA release in liver
fibrosis. Exp Mol Med. 55:269–280. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
165
|
An P, Wei LL, Zhao S, Sverdlov DY, Vaid
KA, Miyamoto M, Kuramitsu K, Lai M and Popov YV: Hepatocyte
mitochondria-derived danger signals directly activate hepatic
stellate cells and drive progression of liver fibrosis. Nat Commun.
11:23622020. View Article : Google Scholar : PubMed/NCBI
|
|
166
|
Calado RT, Regal JA, Kleiner DE, Schrump
DS, Peterson NR, Pons V, Chanock SJ, Lansdorp PM and Young NS: A
spectrum of severe familial liver disorders associate with
telomerase mutations. PLoS One. 4:e79262009. View Article : Google Scholar : PubMed/NCBI
|
|
167
|
Laish I, Mari A, Mannasse B, Hadary R,
Konikoff FM, Amiel A and Kitay-Cohen Y: Telomere length,
aggregates, and capture in cirrhosis. Isr Med Assoc J. 20:295–299.
2018.PubMed/NCBI
|
|
168
|
Kim D, Li AA and Ahmed A: Leucocyte
telomere shortening is associated with nonalcoholic fatty liver
disease-related advanced fibrosis. Liver Int. 38:1839–1848. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
169
|
Carulli L: Telomere shortening as genetic
risk factor of liver cirrhosis. World J Gastroenterol. 21:379–383.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
170
|
Nagaraju GP, Dariya B, Kasa P, Peela S and
El-Rayes BF: Epigenetics in hepatocellular carcinoma. Semin Cancer
Biol. 86:622–632. 2022. View Article : Google Scholar
|
|
171
|
Foglia B, Turato C and Cannito S:
Hepatocellular carcinoma: Latest research in pathogenesis,
detection and treatment. Int J Mol Sci. 24:122242023. View Article : Google Scholar : PubMed/NCBI
|
|
172
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249.
2021.PubMed/NCBI
|
|
173
|
Sagnelli E, Macera M, Russo A, Coppola N
and Sagnelli C: Epidemiological and etiological variations in
hepatocellular carcinoma. Infection. 48:7–17. 2020. View Article : Google Scholar
|
|
174
|
Poon RT, Cheung TT, Kwok PC, Lee AS, Li
TW, Loke KL, Chan SL, Cheung MT, Lai TW, Cheung CC, et al: Hong
Kong consensus recommendations on the management of hepatocellular
carcinoma. Liver Cancer. 4:51–69. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
175
|
Liu P, Tang Q, Chen M, Chen W, Lu Y, Liu Z
and He Z: Hepatocellular senescence: Immunosurveillance and future
senescence-induced therapy in hepatocellular carcinoma. Front
Oncol. 10:5899082020. View Article : Google Scholar : PubMed/NCBI
|
|
176
|
Li F, Huangyang P, Burrows M, Guo K,
Riscal R, Godfrey J, Lee KE, Lin N, Lee P, Blair IA, et al: FBP1
loss disrupts liver metabolism and promotes tumorigenesis through a
hepatic stellate cell senescence secretome. Nat Cell Biol.
22:728–739. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
177
|
Huang Y, Yang X, Meng Y, Shao C, Liao J,
Li F, Li R, Jing Y and Huang A: The hepatic senescence-associated
secretory phenotype promotes hepatocarcinogenesis through
Bcl3-dependent activation of macrophages. Cell Biosci. 11:1732021.
View Article : Google Scholar : PubMed/NCBI
|
|
178
|
Ho TC, Wang EY, Yeh KH, Jeng YM, Horng JH,
Wu LL, Chen YT, Huang HC, Hsu CL, Chen PJ, et al: Complement C1q
mediates the expansion of periportal hepatic progenitor cells in
senescence-associated inflammatory liver. Proc Natl Acad Sci USA.
117:6717–6725. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
179
|
Zheng C, Zheng L, Yoo JK, Guo H, Zhang Y,
Guo X, Kang B, Hu R, Huang JY, Zhang Q, et al: Landscape of
infiltrating T cells in liver cancer revealed by single-cell
sequencing. Cell. 169:1342–1356.e16. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
180
|
Zhou W, Deng J, Chen Q, Li R, Xu X, Guan
Y, Li W, Xiong X, Li H, Li J and Cai X: Expression of
CD4+CD25+CD127Low regulatory T cells and cytokines in
peripheral blood of patients with primary liver carcinoma. Int J
Med Sci. 17:712–719. 2020. View Article : Google Scholar :
|
|
181
|
Schoenberg MB, Li X, Li X, Han Y, Hao J,
Miksch RC, Koch D, Börner N, Beger NT, Bucher JN, et al: The
predictive value of tumor infiltrating leukocytes in hepatocellular
carcinoma: A systematic review and meta-analysis. Eur J Surg Oncol.
47:2561–2570. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
182
|
Zhang CY, Liu S and Yang M: Regulatory T
cells and their associated factors in hepatocellular carcinoma
development and therapy. World J Gastroenterol. 28:3346–3358. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
183
|
Yang Y, Cai Q, Zhu M, Rong J, Feng X and
Wang K: Exploring the double-edged role of cellular senescence in
chronic liver disease for new treatment approaches. Life Sci.
373:1236782025. View Article : Google Scholar : PubMed/NCBI
|
|
184
|
Guo X, Wen S, Wang J, Zeng X, Yu H, Chen
Y, Zhu X and Xu L: Senolytic combination of dasatinib and quercetin
attenuates renal damage in diabetic kidney disease. Phytomedicine.
130:1557052024. View Article : Google Scholar : PubMed/NCBI
|
|
185
|
Islam MT, Tuday E, Allen S, Kim J, Trott
DW, Holland WL, Donato AJ and Lesniewski LA: Senolytic drugs,
dasatinib and quercetin, attenuate adipose tissue inflammation, and
ameliorate metabolic function in old age. Aging Cell.
22:e137672023. View Article : Google Scholar : PubMed/NCBI
|
|
186
|
Zhu Y, Tchkonia T, Pirtskhalava T, Gower
AC, Ding H, Giorgadze N, Palmer AK, Ikeno Y, Hubbard GB, Lenburg M,
et al: The Achilles' heel of senescent cells: From transcriptome to
senolytic drugs. Aging Cell. 14:644–658. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
187
|
Ogrodnik M, Miwa S, Tchkonia T, Tiniakos
D, Wilson CL, Lahat A, Day CP, Burt A, Palmer A, Anstee QM, et al:
Cellular senescence drives age-dependent hepatic steatosis. Nat
Commun. 8:156912017. View Article : Google Scholar : PubMed/NCBI
|
|
188
|
Thadathil N, Selvarani R, Mohammed S,
Nicklas EH, Tran AL, Kamal M, Luo W, Brown JL, Lawrence MM, Borowik
AK, et al: Senolytic treatment reduces cell senescence and
necroptosis in Sod1 knockout mice that is associated with reduced
inflammation and hepatocellular carcinoma. Aging Cell.
21:e136762022. View Article : Google Scholar : PubMed/NCBI
|
|
189
|
Raffaele M, Kovacovicova K, Frohlich J, Lo
Re O, Giallongo S, Oben JA, Faldyna M, Leva L, Giannone AG, Cabibi
D and Vinciguerra M: Mild exacerbation of obesity- and
age-dependent liver disease progression by senolytic cocktail
dasatinib + quercetin. Cell Commun Signal. 19:442021. View Article : Google Scholar
|
|
190
|
Fan Y, Cheng J, Zeng H and Shao L:
Senescent cell depletion through targeting BCL-family proteins and
mitochondria. Front Physiol. 11:5936302020. View Article : Google Scholar : PubMed/NCBI
|
|
191
|
Zhao X, Ogunwobi OO and Liu C: Survivin
inhibition is critical for Bcl-2 inhibitor-induced apoptosis in
hepatocellular carcinoma cells. PLoS One. 6:e219802011. View Article : Google Scholar : PubMed/NCBI
|
|
192
|
Emiloju OE, Yin J, Koubek E, Reid JM,
Borad MJ, Lou Y, Seetharam M, Edelman MJ, Sausville EA, Jiang Y, et
al: Phase 1 trial of navitoclax and sorafenib in patients with
relapsed or refractory solid tumors with hepatocellular carcinoma
expansion cohort. Invest New Drugs. 42:127–135. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
193
|
Gold NM, Ding Q, Yang Y, Pu S, Cao W, Ge
X, Yang P, Okeke MN, Nisar A, Pan Y, et al: Therapeutic potential
of nicotinamide and ABT263 in alcohol-associated liver disease
through targeting cellular senescence. MedComm (2020).
6:e700862025. View Article : Google Scholar : PubMed/NCBI
|
|
194
|
Hikita H, Takehara T, Shimizu S, Kodama T,
Shigekawa M, Iwase K, Hosui A, Miyagi T, Tatsumi T, Ishida H, et
al: The Bcl-xL inhibitor, ABT-737, efficiently induces apoptosis
and suppresses growth of hepatoma cells in combination with
sorafenib. Hepatology. 52:1310–1321. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
195
|
Tse C, Shoemaker AR, Adickes J, Anderson
MG, Chen J, Jin S, Johnson EF, Marsh KC, Mitten MJ, Nimmer P, et
al: ABT-263: A potent and orally bioavailable Bcl-2 family
inhibitor. Cancer Res. 68:3421–3428. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
196
|
Leverson JD, Phillips DC, Mitten MJ,
Boghaert ER, Diaz D, Tahir SK, Belmont LD, Nimmer P, Xiao Y, Ma XM,
et al: Exploiting selective BCL-2 family inhibitors to dissect cell
survival dependencies and define improved strategies for cancer
therapy. Sci Transl Med. 7:279ra402015. View Article : Google Scholar : PubMed/NCBI
|
|
197
|
Cucarull B, Tutusaus A, Subías M,
Stefanovic M, Hernáez-Alsina T, Boix L, Reig M, García de Frutos P,
Marí M, Colell A, et al: Regorafenib alteration of the BCL-xL/MCL-1
ratio provides a therapeutic opportunity for BH3-mimetics in
hepatocellular carcinoma models. Cancers (Basel). 12:3322020.
View Article : Google Scholar : PubMed/NCBI
|
|
198
|
Bourgeois B and Madl T: Regulation of
cellular senescence via the FOXO4-p53 axis. FEBS Lett.
592:2083–2097. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
199
|
Zhang C, Xie Y, Chen H, Lv L, Yao J, Zhang
M, Xia K, Feng X, Li Y, Liang X, et al: FOXO4-DRI alleviates
age-related testosterone secretion insufficiency by targeting
senescent Leydig cells in aged mice. Aging (Albany NY).
12:1272–1284. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
200
|
Dutta Gupta S, Bommaka MK and Banerjee A:
Inhibiting protein-protein interactions of Hsp90 as a novel
approach for targeting cancer. Eur J Med Chem. 178:48–63. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
201
|
Leng AM, Liu T, Yang J, Cui JF, Li XH, Zhu
YN, Xiong T, Zhang G and Chen Y: The apoptotic effect and
associated signalling of HSP90 inhibitor 17-DMAG in hepatocellular
carcinoma cells. Cell Biol Int. 36:893–899. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
202
|
Hu D, Mo X, Luo J, Wang F, Huang C, Xie H
and Jin L: 17-DMAG ameliorates neuroinflammation and BBB disruption
via SOX5 mediated PI3K/Akt pathway after intracerebral hemorrhage
in rats. Int Immunopharmacol. 123:1106982023. View Article : Google Scholar : PubMed/NCBI
|
|
203
|
Saber S, El-Fattah EEA, Abdelhamid AM,
Mourad AAE, Hamouda MAM, Elrabat A, Zakaria S, Haleem AA, Mohamed
SZ, Elgharabawy RM, et al: Innovative challenge for the inhibition
of hepatocellular carcinoma progression by combined targeting of
HSP90 and STAT3/HIF-1α signaling. Biomed Pharmacother.
158:1141962023. View Article : Google Scholar
|
|
204
|
Li L, Wang L, You QD and Xu XL: Heat shock
protein 90 inhibitors: An update on achievements, challenges, and
future directions. J Med Chem. 63:1798–1822. 2020. View Article : Google Scholar
|
|
205
|
Ambade A, Catalano D, Lim A, Kopoyan A,
Shaffer SA and Mandrekar P: Inhibition of heat shock protein 90
alleviates steatosis and macrophage activation in murine alcoholic
liver injury. J Hepatol. 61:903–911. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
206
|
Goyal L, Wadlow RC, Blaszkowsky LS, Wolpin
BM, Abrams TA, McCleary NJ, Sheehan S, Sundaram E, Karol MD, Chen J
and Zhu AX: A phase I and pharmacokinetic study of ganetespib
(STA-9090) in advanced hepatocellular carcinoma. Invest New Drugs.
33:128–137. 2015. View Article : Google Scholar
|
|
207
|
Saber S, Hasan AM, Mohammed OA, Saleh LA,
Hashish AA, Alamri MMS, Al-Ameer AY, Alfaifi J, Senbel A, Aboregela
AM, et al: Ganetespib (STA-9090) augments sorafenib efficacy via
necroptosis induction in hepatocellular carcinoma: Implications
from preclinical data for a novel therapeutic approach. Biomed
Pharmacother. 164:1149182023. View Article : Google Scholar : PubMed/NCBI
|
|
208
|
Syed DN, Adhami VM, Khan N, Khan MI and
Mukhtar H: Exploring the molecular targets of dietary flavonoid
fisetin in cancer. Semin Cancer Biol. 40-41:130–140. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
209
|
Zhou ZS, Kong CF, Sun JR, Qu XK, Sun JH
and Sun AT: Fisetin ameliorates alcohol-induced liver injury
through regulating SIRT1 and SphK1 pathway. Am J Chin Med.
50:2171–2184. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
210
|
Sundarraj K, Raghunath A, Panneerselvam L
and Perumal E: Fisetin inhibits autophagy in HepG2 cells via
PI3K/Akt/mTOR and AMPK pathway. Nutr Cancer. 73:2502–2514. 2021.
View Article : Google Scholar
|
|
211
|
Chilvery S, Bansod S, Saifi MA and Godugu
C: Piperlongumine attenuates bile duct ligation-induced liver
fibrosis in mice via inhibition of TGF-β1/Smad and EMT pathways.
Int Immunopharmacol. 88:1069092020. View Article : Google Scholar
|
|
212
|
Liu X, Wang Y, Zhang X, Gao Z, Zhang S,
Shi P, Zhang X, Song L, Hendrickson H, Zhou D and Zheng G:
Senolytic activity of piperlongumine analogues: Synthesis and
biological evaluation. Bioorg Med Chem. 26:3925–3938. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
213
|
Yakubo S, Abe H, Li Y, Kudo M, Kimura A,
Wakabayashi T, Watanabe Y, Kimura N, Setsu T, Yokoo T, et al:
Dasatinib and quercetin as senolytic drugs improve fat deposition
and exhibit antifibrotic effects in the medaka metabolic
dysfunction-associated steatotic liver disease model. Diseases.
12:3172024. View Article : Google Scholar : PubMed/NCBI
|
|
214
|
Song P, Duan JL, Ding J, Liu JJ, Fang ZQ,
Xu H, Li ZW, Du W, Xu M, Ling YW, et al: Cellular senescence primes
liver fibrosis regression through Notch-EZH2. MedComm (2020).
4:e3462023. View Article : Google Scholar : PubMed/NCBI
|
|
215
|
Wang G, Zhan Y, Wang H and Li W: ABT-263
sensitizes TRAIL-resistant hepatocarcinoma cells by downregulating
the Bcl-2 family of anti-apoptotic protein. Cancer Chemother
Pharmacol. 69:799–805. 2012. View Article : Google Scholar
|
|
216
|
Ma B, Ju A, Zhang S, An Q, Xu S, Liu J, Yu
L, Fu Y and Luo Y: Albumosomes formed by cytoplasmic pre-folding
albumin maintain mitochondrial homeostasis and inhibit nonalcoholic
fatty liver disease. Signal Transduct Target Ther. 8:2292023.
View Article : Google Scholar : PubMed/NCBI
|
|
217
|
Abu-Elsaad NM, Serrya MS, El-Karef AM and
Ibrahim TM: The heat shock protein 90 inhibitor, 17-AAG, attenuates
thioacetamide induced liver fibrosis in mice. Pharmacol Rep.
68:275–282. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
218
|
Abdelhamid AM, Saber S, Hamad RS,
Abdel-Reheim MA, Ellethy AT, Amer MM, Abdel-Hamed MR, Mohamed EA,
Ahmed SS, Elsisi HA, et al: STA-9090 in combination with a statin
exerts enhanced protective effects in rats fed a high-fat diet and
exposed to diethylnitrosamine and thioacetamide. Front Pharmacol.
15:14548292024. View Article : Google Scholar : PubMed/NCBI
|
|
219
|
Augello G, Emma MR, Cusimano A, Azzolina
A, Mongiovì S, Puleio R, Cassata G, Gulino A, Belmonte B,
Gramignoli R, et al: Targeting HSP90 with the small molecule
inhibitor AUY922 (luminespib) as a treatment strategy against
hepatocellular carcinoma. Int J Cancer. 144:2613–2624. 2019.
View Article : Google Scholar
|
|
220
|
Zhang W, Xue H, Zhou C, Zheng Z, Xing M,
Chu H, Li P, Zhang N, Dang Y and Xu X: 7-Aminocephalosporanic acid,
a novel HSP90β inhibitor, attenuates HFD-induced hepatic steatosis.
Biochem Biophys Res Commun. 622:184–191. 2022. View Article : Google Scholar
|
|
221
|
Di Micco R, Krizhanovsky V, Baker D and
d'Adda di Fagagna F: Cellular senescence in ageing: From mechanisms
to therapeutic opportunities. Nat Rev Mol Cell Biol. 22:75–95.
2021. View Article : Google Scholar :
|
|
222
|
Zhang L, Pitcher LE, Prahalad V,
Niedernhofer LJ and Robbins PD: Targeting cellular senescence with
senotherapeutics: Senolytics and senomorphics. FEBS J.
290:1362–1383. 2023. View Article : Google Scholar
|
|
223
|
Harrison DE, Strong R, Sharp ZD, Nelson
JF, Astle CM, Flurkey K, Nadon NL, Wilkinson JE, Frenkel K, Carter
CS, et al: Rapamycin fed late in life extends lifespan in
genetically heterogeneous mice. Nature. 460:392–395. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
224
|
Selvarani R, Mohammed S and Richardson A:
Effect of rapamycin on aging and age-related diseases-past and
future. Geroscience. 43:1135–1158. 2021. View Article : Google Scholar
|
|
225
|
Laberge RM, Sun Y, Orjalo AV, Patil CK,
Freund A, Zhou L, Curran SC, Davalos AR, Wilson-Edell KA, Liu S, et
al: MTOR regulates the pro-tumorigenic senescence-associated
secretory phenotype by promoting IL1A translation. Nat Cell Biol.
17:1049–1061. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
226
|
Lee HS, Kim JY, Ro SW, Kim MS, Kim H and
Joo DJ: Antitumor effect of low-dose of rapamycin in a transgenic
mouse model of liver cancer. Yonsei Med J. 63:1007–1015. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
227
|
Kang HG, Park H, Myong GE, Kim WJ, Mun CE,
Kim CR, You CY, Kim SK, Park MS and Park SI: Beneficial effect of
rapamycin on liver fibrosis in a mouse model (C57bl/6 mouse).
Transplant Proc. 56:701–704. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
228
|
Chao X, Williams SN and Ding WX: Role of
mechanistic target of rapamycin in autophagy and alcohol-associated
liver disease. Am J Physiol Cell Physiol. 323:C1100–C1111. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
229
|
Ge C, Ma C, Cui J, Dong X, Sun L, Li Y and
Yu A: Rapamycin suppresses inflammation and increases the
interaction between p65 and IκBα in rapamycin-induced fatty livers.
PLoS One. 18:e02818882023. View Article : Google Scholar
|
|
230
|
Umemura A, Park EJ, Taniguchi K, Lee JH,
Shalapour S, Valasek MA, Aghajan M, Nakagawa H, Seki E, Hall MN and
Karin M: Liver damage, inflammation, and enhanced tumorigenesis
after persistent mTORC1 inhibition. Cell Metab. 20:133–144. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
231
|
Pallet N and Legendre C: Adverse events
associated with mTOR inhibitors. Expert Opin Drug Saf. 12:177–186.
2013. View Article : Google Scholar
|
|
232
|
Moiseeva O, Deschênes-Simard X, St-Germain
E, Igelmann S, Huot G, Cadar AE, Bourdeau V, Pollak MN and Ferbeyre
G: Metformin inhibits the senescence-associated secretory phenotype
by interfering with IKK/NF-κB activation. Aging Cell. 12:489–498.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
233
|
Xu L, Wang X, Chen Y, Soong L, Chen Y, Cai
J, Liang Y and Sun J: Metformin modulates T cell function and
alleviates liver injury through bioenergetic regulation in viral
hepatitis. Front Immunol. 12:6385752021. View Article : Google Scholar : PubMed/NCBI
|
|
234
|
Gkiourtzis N, Michou P, Moutafi M, Glava
A, Cheirakis K, Christakopoulos A, Vouksinou E and Fotoulaki M: The
benefit of metformin in the treatment of pediatric non-alcoholic
fatty liver disease: A systematic review and meta-analysis of
randomized controlled trials. Eur J Pediatr. 182:4795–4806. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
235
|
Hunt NJ, Lockwood GP, Kang SWS, Pulpitel
T, Clark X, Mao H, McCourt PAG, Cooney GJ, Wali JA, Le Couteur FH,
et al: The effects of metformin on age-related changes in the liver
sinusoidal endothelial cell. J Gerontol A Biol Sci Med Sci.
75:278–285. 2020.
|
|
236
|
Vacante F, Senesi P, Montesano A, Paini S,
Luzi L and Terruzzi I: Metformin counteracts HCC progression and
metastasis enhancing KLF6/p21 expression and downregulating the IGF
axis. Int J Endocrinol. 2019:75701462019. View Article : Google Scholar : PubMed/NCBI
|
|
237
|
Antwi SO, Li Z, Mody K, Roberts LR and
Patel T: Independent and joint use of statins and metformin by
elderly patients with diabetes and overall survival following HCC
diagnosis. J Clin Gastroenterol. 54:468–476. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
238
|
Rauf A, Imran M, Butt MS, Nadeem M, Peters
DG and Mubarak MS: Resveratrol as an anti-cancer agent: A review.
Crit Rev Food Sci Nutr. 58:1428–1447. 2018. View Article : Google Scholar
|
|
239
|
Chen Q, Zhang H, Yang Y, Zhang S, Wang J,
Zhang D and Yu H: Metformin attenuates UVA-induced skin photoaging
by suppressing mitophagy and the PI3K/AKT/mTOR pathway. Int J Mol
Sci. 23:69602022. View Article : Google Scholar : PubMed/NCBI
|
|
240
|
Li S, Han B, Li J, Lv Z, Jiang H, Liu Y,
Yang X, Lu J and Zhang Z: Resveratrol alleviates liver fibrosis
induced by long-term inorganic mercury exposure through activating
the Sirt 1/PGC-1α signaling pathway. J Agric Food Chem.
72:15985–15997. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
241
|
Chai R, Fu H, Zheng Z, Liu T, Ji S and Li
G: Resveratrol inhibits proliferation and migration through SIRT1
mediated post-translational modification of PI3K/AKT signaling in
hepatocellular carcinoma cells. Mol Med Rep. 16:8037–8044. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
242
|
Zhang B, Yin X and Sui S: Resveratrol
inhibited the progression of human hepatocellular carcinoma by
inducing autophagy via regulating p53 and the phosphoinositide
3-kinase/protein kinase B pathway. Oncol Re. 40:2758–2765.
2018.
|
|
243
|
Shaito A, Posadino AM, Younes N, Hasan H,
Halabi S, Alhababi D, Al-Mohannadi A, Abdel-Rahman WM, Eid AH,
Nasrallah GK and Pintus G: Potential adverse effects of
resveratrol: A literature review. Int J Mol Sci. 21:20842020.
View Article : Google Scholar : PubMed/NCBI
|
|
244
|
Pallauf K, Rimbach G, Rupp PM, Chin D and
Wolf IM: Resveratrol and lifespan in model organisms. Curr Med
Chem. 23:4639–4680. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
245
|
Fu J, Deng W, Ge J, Fu S, Li P, Wu H, Wang
J, Gao Y, Gao H and Wu T: Sirtuin 1 alleviates alcoholic liver
disease by inhibiting HMGB1 acetylation and translocation. PeerJ.
11:e164802023. View Article : Google Scholar : PubMed/NCBI
|
|
246
|
Yamazaki Y, Usui I, Kanatani Y, Matsuya Y,
Tsuneyama K, Fujisaka S, Bukhari A, Suzuki H, Senda S, Imanishi S,
et al: Treatment with SRT1720, a SIRT1 activator, ameliorates fatty
liver with reduced expression of lipogenic enzymes in MSG mice. Am
J Physiol Endocrinol Metab. 297:E1179–E1186. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
247
|
He Y, Su Y, Duan C, Wang S, He W, Zhang Y,
An X and He M: Emerging role of aging in the progression of NAFLD
to HCC. Ageing Res Rev. 84:1018332023. View Article : Google Scholar
|
|
248
|
Rastegar M, Marjani HA, Yazdani Y,
Shahbazi M, Golalipour M and Farazmandfar T: Investigating effect
of rapamycin and metformin on angiogenesis in hepatocellular
carcinoma cell line. Adv Pharm Bull. 8:63–68. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
249
|
Smith FC, Stocker SL, Danta M, Carland JE,
Kumar SS, Liu Z, Greenfield JR, Braithwaite HE, Cheng TS, Graham
GG, et al: The safety and pharmacokinetics of metformin in patients
with chronic liver disease. Aliment Pharmacol Ther. 51:565–575.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
250
|
Sato Y, Qiu J, Hirose T, Miura T, Sato Y,
Kohzuki M and Ito O: Metformin slows liver cyst formation and
fibrosis in experimental model of polycystic liver disease. Am J
Physiol Gastrointest Liver Physiol. 320:G464–G473. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
251
|
de Oliveira S, Houseright RA, Graves AL,
Golenberg N, Korte BG, Miskolci V and Huttenlocher A: Metformin
modulates innate immune-mediated inflammation and early progression
of NAFLD-associated hepatocellular carcinoma in zebrafish. J
Hepatol. 70:710–721. 2019. View Article : Google Scholar
|
|
252
|
He Y, Wang H, Lin S, Chen T, Chang D, Sun
Y, Wang C, Liu Y, Lu Y, Song J, et al: Advanced effect of curcumin
and resveratrol on mitigating hepatic steatosis in metabolic
associated fatty liver disease via the PI3K/AKT/mTOR and HIF-1/VEGF
cascade. Biomed Pharmacother. 165:1152792023. View Article : Google Scholar : PubMed/NCBI
|
|
253
|
Elmorsy EA, Elsisi HA, Alkhamiss AS,
Alsoqih NS, Khodeir MM, Alsalloom AA, Almeman AA, Elghandour SR,
Nadwa EH, Khalifa AK, et al: Activation of SIRT1 by SRT1720
alleviates dyslipidemia, improves insulin sensitivity and exhibits
liver-protective effects in diabetic rats on a high-fat diet: New
insights into the SIRT1/Nrf2/NFκB signaling pathway. Eur J Pharm
Sci. 206:1070022025. View Article : Google Scholar
|
|
254
|
Al-Gayyar MMH, Bagalagel A, Noor AO,
Almasri DM and Diri R: The therapeutic effects of nicotinamide in
hepatocellular carcinoma through blocking IGF-1 and effecting the
balance between Nrf2 and PKB. Biomed Pharmacother. 112:1086532019.
View Article : Google Scholar : PubMed/NCBI
|
|
255
|
Evangelou K, Vasileiou PVS,
Papaspyropoulos A, Hazapis O, Petty R, Demaria M and Gorgoulis VG:
Cellular senescence and cardiovascular diseases: Moving to the
'heart' of the problem. Physiol Rev. 103:609–647. 2023. View Article : Google Scholar
|
|
256
|
Li X, Li C, Zhang W, Wang Y, Qian P and
Huang H: Inflammation and aging: Signaling pathways and
intervention therapies. Signal Transduct Target Ther. 8:2392023.
View Article : Google Scholar : PubMed/NCBI
|
|
257
|
Baumann A, Hernández-Arriaga A, Brandt A,
Sánchez V, Nier A, Jung F, Kehm R, Höhn A, Grune T, Frahm C, et al:
Microbiota profiling in aging-associated inflammation and liver
degeneration. Int J Med Microbiol. 311:1515002021. View Article : Google Scholar : PubMed/NCBI
|
